Colorectal cancer metastasis is frequently driven by a cellular repair pathway controlled by the protein YAP1, which can be abnormally activated by dietary lipids such as ceramides found in high-fat diets. Researchers publishing in the journal Science identified this mechanism, showing that blocking the enzymes responsible for ceramide production prevents tumor cells from triggering the regenerative program necessary to seed secondary tumors in the liver.
Most colon cancer deaths stem from the spread of tumor cells beyond the colon, predominantly to the liver. While numerous genetic mutations drive the development of primary tumors, researchers have lacked a clear genetic signature distinguishing metastatic cells from primary tumors. To investigate epigenetic drivers, investigators utilized tumor organoids derived from mouse models and colorectal cancer patients to examine how cancer cells acquire the capacity to spread.
The Role of YAP1 and Intestinal Regeneration
The study revealed that metastatic colon cancer cells share a single defining characteristic: the activation of the YAP1 protein program. In healthy tissue, YAP1 works with partner factors to regulate genes associated with development, stem cell maintenance, and tissue repair. During severe injury or infection in the gut, this regenerative response operates through a rare, fetal-like cell type that briefly appears to rebuild the intestinal lining.
According to MIT postdocs Swagata Goswami, Qiming Zhang, and Abdullah Burak Yildiz, who served as lead authors of the study, tumor cells hijack this natural healing program to drive metastatic progression. Activation of these specific genes allows cancer cells to break free from the primary tumor site and migrate to distant organs, most commonly the liver and lungs.
High-Fat Diets, Ceramides, and Metastasis Risk
Investigators discovered that animal models fed a high-fat diet activated YAP1 to a significantly greater degree than mice consuming a standard, healthy diet. High-fat diets trigger the activation of specific enzymes that manufacture ceramides, which are a class of lipid molecules.
The production of ceramides removes the molecular brake that normally maintains YAP1 in an inactive state. Once released, YAP1 translocates into the cell nucleus, where it switches on its target genes and initiates the metastatic cascade.
Senior authors Omer Yilmaz—director of the MIT Stem Cell Initiative, biology professor at MIT, and gastrointestinal pathologist at Beth Israel Deaconess Medical Center—along with Nilay Sethi of Harvard Medical School and Dana-Farber Cancer Institute, and Alpaslan Tasdogan of University Hospital Essen and the German Cancer Consortium (DKTK), noted that shutting down ceramide-producing enzymes stops tumor cells from engaging this regenerative program.
Human Data and Implications for Treatment
To evaluate whether the animal findings translate to humans, the research team analyzed RNA sequencing data from colorectal cancer patients. The analysis showed that YAP1 expression was notably higher in metastatic cancer cells compared to primary tumors.
Patients with a higher body mass index (BMI) demonstrated elevated expression of the genes activated by YAP1 relative to normal-weight patients, and individuals with higher levels of those specific gene products experienced lower overall survival rates. The study authors emphasize that while these pathways correlate with body mass, the YAP1 regenerative program itself is not limited strictly to obesity.
The identification of this druggable pathway points toward potential preventative interventions. By targeting YAP1 or the specific enzymes responsible for ceramide synthesis, future therapeutic strategies could potentially block the spread of colon cancer following surgical resection of primary tumors.
Worth a look